antibody_production_3

Discover how Contract Research Organizations (CROs) accelerate therapeutic development through specialized expertise, cost-effective solutions, scalability, and biotech innovation.

Biointron's SVP of R&D, Lei Shi, PhD, discussed the processes of accelerating early discovery through HTP and high-speed antibody production during the Antibody Engineering & Therapeutics US 2023 conference in San Diego. Below is a summary of the talk.

Plasma cells secrete vast amounts of antibodies. Biointron describes their differentiation from B cells and the importance of this process in immune defense.

Antigen recognition initiates immune defense. Biointron explains how B cell activation shapes antibody production and drives effective immune responses.

Antibodies defend against disease and power modern biotech. Biointron shares ten fascinating facts that highlight their versatility and impact in research and therapy.

Learn how recombinant antibody production uses genetic engineering to create highly specific antibodies, replacing traditional methods for therapeutic and diagnostic use.

Examine how CHO cell line development and optimized upstream processing improve therapeutic antibody production, ensuring high yields, consistent quality, and clinical efficacy.

Therapeutic antibody discovery begins with screening. Biointron applies ELISA, SPR, and AI-driven tools to identify high-affinity antibodies with precision and speed.

Single-chain variable fragments (scFvs) combine small size with strong binding. Biointron highlights their history, uses in diagnostics and therapy, and production expertise.

Biointron streamlines antibody production and purification, applying recombinant expression, hybridoma methods, and chromatography techniques to ensure purity and performance.

From hybridoma to recombinant platforms, Biointron leads innovations in antibody production and engineering, enabling faster, more flexible, and reliable research solutions.

Biointron’s ISO 9001:2015-certified manufacturing standards ensure reliable, high-quality antibody production with rigorous QC processes and global CRO expertise.

Learn how antibody fragmentation enhances research and therapy using Fab, scFv, and VHH fragments for targeted drug delivery, diagnostics, and tissue penetration.

Speed drives better decisions. Discover how high-throughput recombinant antibody production shortens design-test cycles and accelerates research pipelines worldwide.

Explore ethical questions around antibody production in animals, the 3Rs principle, and how recombinant technology reduces animal use while ensuring high-quality science.